IMDX logo

INSIGHT MOLECULAR DIAGNOSTIC

IMDXNASDAQ
🏆 #3943 by market capEarnings Nov 5US Equity
$3.17▲ $0.01 (+0.32%)
Pre-market · at close
🔔
Track IMDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.3%
7d▲ 11.2%
14d▲ 3.4%
30d▼ 6.1%
ytd▼ 57.8%
1y▼ 44.7%
🏦Market Cap
$104M
Small Cap
📈Revenue Growth (YoY)
-60.8%
Declining
📊Gross Margin
48.3%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
61.5x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$3.09 – $3.17
52-Week Range
$2.42 – $8.51
Volume (shares)
6,240
Avg Volume (shares)
—
Shares Outstanding
32.7M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$239,000
P/E Ratio
—
P/S Ratio
61.5x
EPS (TTM)
$-1.48
Dividend Yield
—
Dilution (1yr)
+75.3%
IMDX logo

INSIGHT MOLECULAR DIAGNOSTIC

IMDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▲ +115.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
4.7%▼ −88.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$31M▼ −49.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$25M▲ +19.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.5M▲ +75.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$3M YoY
StockOtter · stockotter.space

About INSIGHT MOLECULAR DIAGNOSTIC

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.